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Abstract: 
OBJECTIVES: To establish interobserver reproducibility of tumour volumetry on individual 
multiparametric(mp) prostate MRI sequences, validate measurements with histology and 
determine whether functional to morphological volume ratios reflect Gleason score.  
METHODS: Forty-one men with prostate cancer treated with prostatectomy (cohort 1) or radical 
radiotherapy (cohort 2) who had pre-treatment mp (T2-W, DW-, DCE-) MRI were studied 
retrospectively. Dominant intraprostatic lesions (DIPLs) were manually delineated on each 
sequence and volumes compared between observers (n=40 analysable) and with radical 
prostatectomy (n=20). Volume ratios of DW- and DCE- to T2-W MRI were documented and 
compared between Gleason grade 3+3, 3+4 and 4+3 or greater categories.  
RESULTS: Limits of Agreement of DIPL volumes between observers were: T2-W 0.9, -1.1 cm3, 
DW-MRI 1.3, -1.7 cm3, DCE-MRI 0.74, -0.89 cm3. In cohort 1, T2-W volumes overestimated 
fixed specimen histological volumes, (+33% observer 1, +16% observer 2);  DW- and DCE-MRI 
underestimated histological volume, the latter markedly so (-32% observer 1, -79% observer 2). 
Differences between T2-W, DW- and DCE-MRI volumes were significant (p<10-8). The 
proportional volume of DW- (73.9+18.1 % observer 1, 72.5+21.9% observer 2) and DCE-MRI 
volume (42.6+24.6% observer 1, 34.3+24.9% observer 2) to T2-W volume was significantly 
different (p<10-8) but these volume ratios did not differ between Gleason grade. 
CONCLUSIONS: The T2-W MRI DIPL volume variability between observers and with 
histology best reflects the GTV for radiotherapy planning. The volume of cellular tumour 
represented by DW-MRI is greater than the vascular (DCE) abnormality; ratios of both to T2-W 
volume are independent of Gleason score.   
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ADVANCES IN KNOWLEDGE:  
1. Manual volume measurement of tumour is reproducible within 1cm3 between observers 
on all sequences, confirming suitability across observers for radiotherapy planning.  
2. Volumes derived on T2-W MRI most accurately represent in vivo lesion volumes.  
3. The proportion of cellular (DW-) or vascular (DCE-) volume to morphological (T2-W) 
volume is not affected by Gleason score. 
 
Keywords: 
multiparametric MRI; tumour volume; prostate cancer; tumour dominant intraprostatic lesion; 
histopathological validation, diffusion-weighted, dynamic contrast-enhanced, volumetry 
Abbreviations: 
MRI – Magnetic Resonance Imaging,  CT – Computerized Tomography, DIPL – Dominant 
IntraProstatic Lesion, OAR – Organ(s)-At-Risk, mpMRI – multiparametric Magnetic Resonance 
Imaging, ADC – Apparent Diffusion Coefficient, DWI – Diffusion Weighted Imaging, DCE – 
Dynamic Contrast Enhanced sequence, GTV – Gross Tumour Volume, ROI – Region Of 
Interest, IRB - Institutional Review Board. 
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Introduction:  
The soft tissue contrast on T2-W Magnetic Resonance Imaging (MRI) is preferred over x-ray 
computerized tomography (CT) for prostate tumour identification, staging 1-4 and defining the 
dominant intraprostatic lesion (DIPL) 5. Furthermore, additional information available from 
Diffusion-Weighted Imaging (DW-) and Dynamic Contrast Enhanced (DCE-) MRI techniques, 
collectively termed multiparametric (mp)MRI, may be exploited to improve sensitivity and 
specificity for tumour identification over T2-W imaging alone 6.  Accurate definition of gross 
tumour volume (GTV) derived from these images is essential in planning radiation therapy 7, 
particularly when giving boost doses to the DIPL 8: overestimation of the GTV increases the risk 
of radiation-induced complications to Organs-At-Risk (OARs) such as the rectal wall, and 
underestimation reduces the long-term efficacy of treatment 9. However, as there is increasing 
evidence that the volumes defined on individual mpMRI sequences are significantly different 
from each other 10 and depend on underlying histology 11, 12, the optimal sequence on which to 
outline the GTV remains to be established.  
Traditionally, tumour outlines are done on T2-W images for radiation therapy planning. 
Although this involves simultaneous viewing of all mpMRI images 13, the specific and 
independent influence of the DW- and DCE-MRI identified tumour, which may vary with 
Gleason grade, on the morphological (T2-W) outlines has not been documented. A recent large 
study showed that the maximum volume measured on mpMRI correlated best with histology 14. 
The purpose of this study therefore was to establish the interobserver reproducibility of prostate 
tumour volumetry on individual sequences obtained from mpMRI, validate the measurements 
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against histology and determine whether the proportion of cellular (DW-) or vascular (DCE-) 
volume to morphological (T2-W) volume reflects Gleason score.  
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Methods:  
Patients:  
Imaging data was obtained from 41 men with prostate cancer (mean age  66.7 ± 7.6 years, PSA 
range 3.0 – 32.0 ng/mL, clinical grade T1-T3, Gleason grade 6-8) who had been enrolled 
consecutively in 2 unrelated prospective studies approved by the local Institutional Review 
Board (IRB) and had given written consent for use of their data. Acquired images were therefore 
analysed retrospectively. All patients had mpMRI with positive histology on a standardized 8-10 
core randomly sampled transrectal ultrasound guided biopsy done between 4 and 12 weeks 
previously (median 85 days, range 8-231 days). All patients were treatment naïve at the time of 
scanning. The first 20 (Cohort 1) were treated with radical prostatectomy and the latter 21 
(Cohort 2) underwent radiation therapy with dose-boosting to the DIPL. In cohort 1, mpMRI was 
performed a mean of 16.7 days (median 12 days, range 1–54) prior to prostatectomy. In Cohort 1 
3 were Gleason grade 3+3, 12 were 3+4 and 5 were 4+3 or greater. In Cohort 2, 5 were Gleason 
grade 3+3, 10 were 3+4 and 6 were 4+3 or greater. 
 
Image Acquisition:  
All imaging was done with an endorectal coil. Cohort 1 was studied at 1.5-T and 55ml of room 
air was used for inflation of the balloon. Cohort 2 was studied at 3-T and the balloon was filled 
with 60ml of perfluorocarbon to reduce susceptibility artefact. Hyoscine butyl bromide 20 mg 
was administered intramuscularly in all cases. T2-W images were obtained in 3 planes 
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orthogonal to the prostate at both field strengths supplemented by position matched DW- and 
DCE-MRI sequences in the axial plane.  
At 1.5-T (Magnetom Avanto, Siemens Medical Systems, Erlangen, Germany), a fast spin-echo 
T2-W sequence (FSE, TR/effective TE = 5500/96, echo-train length 16, FoV 140mm, matrix 
size 512 × 512, 20 contiguous slices, slice thickness 3.0 mm) was used together with single-shot 
echo-planar DW sequence (TR/TE = 2500/69, FoV 200mm, matrix size 128 × 128, 12 
contiguous slices, slice thickness 4 mm, b values, 0, 300, 500, and 800 s/mm2) with three 
orthogonal diffusion directions, resulting in a rotationally invariant trace image at each b-value. 
A gradient-echo sequence was used for DCE imaging (GRAPPA, TR/TE = 4.1 / 1.77 ms, FoV  
300mm, flip angle 30°, matrix 128 x 128, 8 contiguous 5.0mm slices at 90 time points, temporal 
resolution 3.52 secs during intravenous administration of 0.2 mL/kg of gadopentetate 
dimeglumine [Magnevist, Bayer Schering Pharma] at 3.0 mL/s). Registration images with the 
same measurement parameters and positions were acquired with flip angles of 2°, 8°, 16°, 24°, 
and 30° to enable estimation of T1 before contrast administration.   
 
At 3.0-T (Achieva, Philips, Best, Netherlands), a FSE T2-W sequence was also utilized (FSE, 
TR 2627 ms, TE 110 ms, FoV 120 mm, slice thickness 2.2 mm, matrix 220 × 184 extrapolated to 
256 × 256) together with a single shot echo-planar DW sequence (TR 5000 ms, TE 54 ms, b = 0, 
100, 300, 500, 800 s/mm2, FOV 100 mm, slice thickness 2.2 mm, matrix 80 × 79 extrapolated to 
176 × 176).  A gradient-echo sequence was used for DCE imaging (3D FFE, SPAIR fat 
suppression, TR/TE = 4.4 / 2.1 ms, FoV  120mm, flip angle 16°, matrix 76 x 98 extrapolated to 
224 x 244, 24 contiguous 2.3mm slices at 20 time points, temporal resolution 12 secs during 
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intravenous administration of 0.2 mL/kg of gadoterate meglumine [Dotarem, Guerbet, USA] at 
2.0 mL/s). Registration images with the same measurement parameters and positions were 
acquired with a flip angle of 16° to enable estimation of T1 before contrast administration. The 
phase-encoding gradient was left to right in all cases to minimize motion artefacts in the prostate. 
An external pelvic phased-array coil was used to acquire axial T1-W and T2-W images through 
the pelvis to assess lymph node status as part of the routine clinical examination at both 1.5-T 
and 3-T, but these images did not form part of the evaluation in this study. 
 
 
Image Analysis:  
Anonymised images were analysed on dedicated reporting workstations. Axial T2-W images, 
isotropic ADC maps calculated from monoexponential fit of the DW- data from all b-values, and 
grey-scale DCE images at peak contrast enhancement (range 58.5-62.5sec) had manual ROIs 
drawn around the DIPL on a 2D slice-by-slice basis. The DIPL was defined as the largest visible 
low signal intensity lesion on T2-W images with a corresponding subjective ADC reduction on 
DW-MRI from an octant with a positive biopsy. In cohort 1, the location of the DIPL was 
subsequently confirmed on the prostatectomy specimen. Smaller secondary lesions were ignored 
as these were not targets for dose boosting. Outlining was performed by free-hand drawing using 
a mouse-controlled cursor; margin recognition was based on the subjective assessment of the 
imaging features for each sequence according to current ESUR mpMRI guidelines 15. T2-W 
images were assessed for regions of well-defined low T2-W signal, ADC maps for regions of 
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restricted diffusion, and DCE sequences for regions of brisk contrast uptake and early washout 
(Figure 1). ROI delineation on each sequence was done separately on a different occasion at least 
a week later to minimise possible memorisation of tumour margins.  
GTVs were calculated by multiplying stacked ROI areas generated by the workstation software 
by sequence-specific slice thickness. A radiologist with 4 years prostate mpMRI experience 
performed all the DIPL ROI assessments. In addition, a second observer with 20 years’ 
experience of prostate MRI, blinded to the first observer’s ROIs, repeated identical assessments. 
Both observers were also blinded to the histopathological data. 
 
Histopathological analysis:   
All patients in cohort 1 underwent prostatectomy. The prostate was sectioned at 4 mm intervals 
in a plane perpendicular to the gland’s posterior surface using a specially devised slicer to ensure 
accuracy of slicing 16. Formalin fixed and paraffin wax embedded whole mount histopathological 
slides were prepared. The slicing axis matched the axial image acquisition angle so that stained 
sections from the embedded slices matched the imaging slices closely. Although the slice 
thickness did not match the imaging slice thickness, the segmentation of the whole tumour 
volume on both imaging and histology meant that slice by slice correlation of imaging with 
histology was not required. Tumour volumes of the DIPL were demarcated by a specialist 
histopathologist (Figure 1). The whole-mount slides were subsequently overlaid with a 1x1mm 
translucent grid sheet and photographed over a light source. Histopathological tumour volumes 
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of DIPLs were calculated by manual counting of overlying 1mm2 grid squares, multiplied by the 
histological slice thickness.  
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Statistical Analysis: 
Differences between the two observers for each sequence and histology were assessed using 
Bland-Altman plots and Limits of Agreement. The agreement was also assessed with a Pearson’s 
correlation coefficient. 
Analysis of Variance (ANOVA) was used to assess inter-sequence volume differences as well as 
differences in relative volumes between sequences across the 3 Gleason grade categories (3+3, 
3+4, and 4+3 or greater). Paired-t-tests were used to detect significant differences between 
mpMRI volumes and histology for both observers. 
A p-value of <0.05 was taken to be significant in all statistical tests. Analysis was performed in 
Microsoft Excel and SPSS v23. Bland-Altman plots were produced in GraphPad Prism v6.07. 
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Results:  
One patient in cohort 2 had no DCE-MRI data, and artefacted T2-W data and was excluded from 
subsequent analysis.  
 
Tumour Volume Variability 
Differences between observers for T2-W, DW-MRI and DCE-MRI sequences:  
GTVs drawn on T2-W images for both cohorts ranged from 0 to 7.0 cm3 (mean 2.4 ± 1.93 cm3) 
for observer 1 and from 0 to 7.2cm3 (mean 2.29 ± 1.93 cm3) for observer 2. Corresponding data 
for DW- and DCE-MRI are given in Table 1. Differences between volumes derived from all 3 
sequences were significant for both observers (ANOVA, p<10-8). Tumour volumes were smaller 
in cohort 1 than cohort 2 (Cohort 1: 1.5+ 1.6 cm3 for observer 1 vs 1.8 + 1.9 cm3 for observer 2 
and Cohort 2: 3.1 + 2.0 cm3 for observer 1 and 3.0 +1.9 cm3 for observer 2) 
Pearson’s correlation tests demonstrated that interobserver GTVs for each sequence were 
significantly positively correlated at the 0.01 level (2-tailed), r =0.96 (T2-W), 0.94 (DW-MRI) 
and 0.92 (DCE-MRI). Limits of Agreement for interobserver variation in volumetry from each of 
the 3 sequences were: T2-W 0.9, -1.1 cm3, DW-MRI 1.3, -1.7 cm3, DCE-MRI 0.74, -0.89 cm3; 
corresponding Bland-Altman plots are given in Figures 2 A, B and C respectively.  
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Differences between mpMRI sequences and histology (cohort 1):  
Histological volumes ranged from 0.04 to 4.72cm3 (mean 1.46 ± 1.50 cm3). One patient’s tumour 
was not detected on any mpMRI sequence but had a volume of 0.04cm3 on histology. T2W-MRI 
GTVs overestimated histological volumes by 33 + 76% (observer 1) and 16 + 67% (observer 2) 
but had the highest correlation coefficient (r = 0.97 observer 1, 0.93 observer 2, p<0.0001). DW-
MRI and DCE-MRI tended to underestimate histological volume (Table 2). Paired t-tests found 
that mean DCE-MRI GTVs were consistently and significantly different from histology 
(p=0.001 observer 1 and 0.0003 observer 2), whereas T2-W GTV differed from histology in 
observer 1 only (p=0.005) and DW-MRI differed from histology in observer 2 only (p=0.006). 
Bland-Altman plots for each sequence against histology with Limits of Agreement are 
exemplified for observer 1 in Figure 3.  
Average volumes from all 3 sequences in cohort 1 were 1.33 + 1.46 cm3 for observer 1 and 1.05 
+ 1.23 cm3 for observer 2 (Table 2). A paired t-test showed no difference between this average 
volume and histology for observer 1 (p=0.2), although differences for observer 2 were significant 
(p=0.004). 
 
Functional (DW- and DCE-) to morphological (T2-W) MRI tumour volume ratios and 
their relationship with Gleason score: 
As assessed by cognitive fusion, there was a >90% overlap between ROIs from each sequence 
with each other. DW- and DCE-MRI derived volumes were consistently smaller than T2-W 
volumes: DW- to T2-W MRI ratios were 73.9 + 18.1 % for observer 1 and 72.5 + 21.9% for 
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observer 2. DCE- to T2-W MRI volume ratios were even lower (42.6 + 24.6% for observer 1, 
34.3 + 24.9% for observer 2). . The proportion of the T2-W volume represented by the DW-MRI 
volume and the DCE-MRI volume was significantly different (ANOVA, p<10-8).  
Gleason grade was determined at prostatectomy in cohort 1 and pre-treatment in cohort 2. Eight 
patients had Gleason score 3+3 tumours, 21 were Gleason score 3+4 and 11 were Gleason score 
4+3 or greater. DW-MRI to T2-W volume ratios in the 3 Gleason categories were 75.4 + 15.9%, 
72.6 + 18.9% and 75.2 + 19.4% respectively for observer 1 and 68.9 + 17.8%, 67.7 + 19.3% and 
84.2 + 26.1% for observer 2. DCE-MRI to T2-W volume ratios in the 3 Gleason categories were 
44.9 + 12.2%, 39.9 + 27.4% and 45.7 + 27.0% respectively for observer 1 and 33.5 + 23.4%, 
33.8 + 24.8% and 35.8 + 28.1% for observer 2. There were no significant differences in DW- 
and DCE- to T2-W MRI tumour volume ratios between the 3 Gleason grade categories for either 
observer (ANOVA, p>0.05), indicating no differences in the functional to morphological 
volumes with Gleason grade. 
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Discussion: 
We have established that manual ROI delineation of DIPL is reproducible for the purposes of 
radiotherapy planning between two observers with ~1 cm3 limits of agreement on T2-W MRI. 
Both observers interpreted the mpMRI in accordance with ESUR guidelines. Additionally, they 
outlined in optimal ambient conditions for their individual preferences and had the ability to 
manipulate the window, brightness and magnification for decisions regarding tumour margins. 
Differences in observer perception of feature boundaries are likely to reflect the consistently 
lower measurements of observer 2. Although differences in lesion conspicuity due to different 
sequences and scanners will also be a factor, this study aimed to establish variability in the 
presence of these variations. Furthermore, as the diffusion-weighted image provided the most 
definitive contrast for lesion identification, its independence of field-strength re-inforces the 
validity of the findings across the 2 field-strengths used in this study. The concordance of each 
observer’s measurements with histology however, remains the definitive test of the viability of 
the method. In practical terms, the measured tumour volume differed between observers by 1cm3 
for T2-W images in the largest tumours in our cohort which should not cause differences in 
radiation therapy plans made on images outlined by different observers because of the addition 
of substantial additional margins when delineating a clinical target volume around the GTV.  
We have demonstrated a correlation between mpMRI derived tumour volumes with histology 
that is similar to others 10, 14, 17-19. In addition, we have shown that DIPL tumour volumes defined 
on the T2-W images were consistently larger than on DW- or DCE-MRI. Although they 
overestimate histological volumes, they are best suited to delineating the margins of the DIPL for 
radiation dose boosting, especially as a post-resection shrinkage factor of up to 1.15 in 
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histological samples 17 must be allowed for. Shrinkage is due to formalin fixation and was 
unavoidable in our study as the tissue was preserved immediately post-resection for optimal 
diagnostic purposes. In an early work Ponchetti et al showed that T2-W images overestimated 
small tumours by as much as 58%, however their MRI scans were done post-biopsy which may 
have confounded their MRI measurements 19.  In comparison, a study by Cornud et al 20 
underestimated histology in nearly half the cases (49%) with a larger mean difference (-0.56cm3) 
than we demonstrated (-0.08 to 0.30cm3).  A recent large study measuring all visible lesions in 
202 patients also concluded that all sequences underestimated true volume and that the 
maximum volume from all sequences most closely matched histological volume. These results 
and those of others 21, 22 are likely to be influenced by the non-recognition on mpMRI of small, 
low Gleason score disease.  
Estimation of tumour size has also been done on T2-W imaging using a maximal dimension 
approach utilising visual assessment of functional parameters to support the T2-W measurements 
23. Although these data correlate well with histological volumes, they also have been noted to 
underestimate them 24. Other studies have used the functional information to define the T2-W 
ROIs, but have not interrogated the sequences individually 12. Where individual sequences have 
been investigated, e.g. DCE-MRI comparison with histology 25, the focus has been on technical 
developments and comparison with histology, rather than on investigating the relationship of 
volumetry derived from individual sequences. The only other study comparing inter-sequence 
differences reported data from a small data set of 5 patients and, contrary to our findings, 
demonstrated no significant differences in GTVs between sequences as measured by 6 observers 
26.  
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It is accepted that a combination of both T2-W and DW-MRI improves cancer detection and 
localisation 21, 27. Use of a second additional functional technique such as DCE-MRI has been 
shown to further improve sensitivity 28 for tumour detection.  In the assessment of volume on the 
other hand, the addition of DW- and DCE-MRI sequences to T2-W assessments has been 
reported to influence interobserver variability of tumour outlining 9.  The mean differences 
between observers on each of the 3 sequences in this study was <28%, smaller than the mean 
inter-sequence differences of up to 70%. T2-W sequences remain the preferred choice on which 
to delineate prostate tumour in current practice as their higher spatial resolution and low 
geometric distortion enables registration with CT images used for radiation therapy planning. As 
DW- techniques improve and thresholding of quantified ADC allows automated segmentation of 
tumour this may change, giving preference to semi-automated segmentation on ADC maps. 
We have additionally shown that differences between T2-W and DW- or DCE-MRI derived 
GTVs scale consistently with tumour volume. These results suggest that the volume of neo-
angiogenesis is smaller than the volume of abnormal cellular morphology demonstrated on T2-W 
or on DW-MRI respectively. The significant differences between GTVs derived from DCE-MRI 
compared with those from both other sequences and histology also may be in part due to the 
lower spatial resolution of this sequence.  
Although whole mount histopathology is regarded as a gold standard for correlating image-
derived tumour volume measurements, it should be noted that this technique also has innate 
margins of error and is subject to operator-dependent variation depending on experience and the 
equipment available. There is also documented variability in the interpretation and grading of 
Gleason grades 29, and substantial variability has been reported in the current clinical volume 
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estimation methods 30. In our study, to minimize slice width variations we used a specially 
devised slicer to mitigate these effects. All samples were processed in the same manner and 
tumours demarcated by one histopathologist to reduce intra-operator variability. 
All imaging in our study was performed with an endorectal coil which causes posterior 
deformation of the gland. Although this has potential for error when performing 2-D 
measurements, we would not expect an influence on volume measurements where tumour ROIs 
are defined on all slices with visible tumour. Histological assessments of tumour were limited by 
manual assessments of photographs with an overlain grid, but this has provided good correlation 
of imaging and pathological volumes in other tumour types 31, 32. Digital analysis of 
histopathological volumes (planimetry) 33 is more robust where available.  
A limitation of our data is the lack of information on spatial conformity of ROIs between 
sequences, which was assessed only by visual cognitive fusion to confirm concordance. In 
previous work aimed at identifying the index lesion, this has proved time-consuming with 
marginal improvements over cognitive fusion by an experienced observer 34. In addition, field 
inhomogeneity at air-tissue interfaces can cause distortions and lead to errors in EPI based DWI, 
particularly at higher field strengths. However, the rectal balloon was filled with perfluorocarbon 
for our 3T data acquisition, minimising any such distortions. At 1.5T, being the most distorted, 
the volume measurements on DWI corresponded most closely with histology, indicating that 
distortion is not the key factor in measurement error of the DIPL. Another limitation of our study 
was the use of the peak enhancement DCE-MRI sequences for tumour delineation rather than the 
quantitative DCE parameter maps (Ktrans, kep, ve). It is unlikely however that this would have 
yielded GTVs from the DCE-MRI data that were significantly different.  
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In summary, we have established that mpMRI-derived GTV measurements of DIPLs derived 
from T2-W, DW-MRI and DCE sequences are reproducible between observers. GTV is largest 
on T2-W images and smallest on DCE-MRI images, and T2-W GTVs best approximate to in 
vivo tumour volume. Therefore, GTV should be delineated on T2-W images when defining the 
DIPL for radiation dose boosting. Differences in volumes derived from T2-W, DW- and DCE-
MRI images are highly significant reflecting differences in cellular and vascular proportions; the 
proportion of the T2-W volume represented by the DW- and DCE-MRI volume in this sample 
were independent of Gleason grade. 
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Figure Legends: 
 
Figure 1 Comparison of intersequence volumes with histology: Transverse T2-W (A), 
Diffusion-weighted (B) and Dynamic Contrast enhanced image at 30 secs post injection of 
gadoterate meglumine (C). Tumour outlines drawn on 3 separate occasions by observer 1 are 
overlaid. The volume in A was largest, and the volume in C smallest, although overlap between 
the outlines is noted in all cases. Whole-mount histological specimen at prostatectomy (D) 
confirms the presence of tumour at that location. 
 
Figure 2: Bland-Altman plots showing differences in tumour volumetry between observers on 
T2-W (A), Diffusion Weighted (B) and Dynamic Contrast Enhanced (C) MRI in all patients 
(cohorts 1 and 2, n=40). The mean difference (solid line) and Limits of Agreement (dashed lines) 
representing + 1.96 SD from the mean are given. 
 
Figure 3: Bland-Altman plots showing differences in tumour volumetry with histology for 
observer 1 on T2-W (A), Diffusion Weighted (B) and Dynamic Contrast Enhanced (C) MRI in 
patients undergoing prostatectomy (cohort 1, n=20). The mean difference (solid line) and Limits 
of Agreement (dashed lines) representing + 1.96 SD from the mean are given. 
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Table 1: Mean, standard deviation and median volume of dominant intraprostatic tumour lesion 
on each mpMRI sequence for  all patients (cohorts 1 and 2, n=40) and for cohort 1 alone (n=20). 
Volume data derived from prostatectomy samples in cohort 1 is shown for comparison.  
  Observer 1 Observer 2 Histology 
T2-W Mean + SD (cm3) 
(All) 
2.40 + 1.93 2.29 + 1.93  
Median (cm3) 
(All) 
1.77 1.60  
Mean + SD (cm3) 
(cohort 1) 
1.84 + 1.85 1.54 + 1.60 1. 46 + 1.5 
Median (cm3) 
(cohort 1) 
1.1 1.01 0.71 
DW-MRI Mean + SD (cm3) 
(All) 
1.77 + 1.58 1.62 + 1.43  
Median (cm3) 
(All) 
1.17 1.19  
Mean + SD (cm3) 
(cohort 1) 
1.46 + 1.70 1.13 + 1.35  
Median (cm3) 
(cohort 1) 
0.79 0.61  
DCE-MRI Mean + SD (cm3) 
(All) 
1.01 + 0.99 0.9 + 1.1  
Median (cm3) 
(All) 
0.82 0.71  
Mean + SD (cm3) 
(cohort 1) 
0.68 + 0.98 0.48 + 0.88  
Median (cm3) 
(cohort 1) 
0.33 0.15  
Average of 
all 
sequences 
combined 
Mean + SD (cm3) 
(All) 
1.73 + 1.44 1.62 + 1.43  
Median (cm3) 
(All) 
1.27 1.16  
Mean + SD (cm3) 
(cohort 1) 
1.33 + 1.46 1.05 + 1.23  
Median (cm3) 
(cohort 1) 
0.71 0.56  
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Table 2: Differences between volumes of the of dominant intraprostatic tumour lesion derived from each 
sequence for each observer and volumes derived from whole-mount prostatectomy specimens  
 
 T2W vs. histology 
% and absolute (cm3) 
difference 
DWI vs. histology 
% and absolute 
(cm3) difference 
DCE vs. histology 
% and absolute 
(cm3) difference  
Average of 3 sequences 
vs. histology 
% and absolute (cm3) 
difference 
Observer 1 
Mean + SD 
33.2 + 76.3% 
0.38 + 0.53 cm3 
2.5 + 57.8 % 
0.0 + 0.58 cm3 
-31.6 + 97.8 % 
-0.78 + 0.91 cm3 
-7.5 + 49.1 % 
-0.13 + 0.44 cm3 
Observer 2 
Mean + SD 
16.4 + 67.5 % 
0.07 + 0.57 cm3 
-26.1 + 36.4 % 
-0.33 + 0.48 cm3 
-79.3 + 28.3 % 
-0.98 + 0.98 cm3 
-29.7 + 35.6 % 
-0.41 + 0.56 cm3 
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